NRSN · NeuroSense Therapeutics Ltd. · Financials
Market Cap
$12.60M
Shares
37.94M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$11.13M
-9%
FY2025
Diluted EPS
-$0.44
+18.5%
FY2025
Operating Cash Flow
-$7.67M
+24.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| $6.23M | $5.7M | $7.27M | $5.59M | $1.39M | — | — | |
| $4.86M | $4.2M | $4.78M | $4.97M | $2.51M | $393K | $337K | |
| — | — | $97K | $89K | $3000 | $3000 | — | |
| — | — | — | $77K | $19K | — | — | |
| -$11.09M | -$9.9M | -$12.05M | -$10.55M | -$5.59M | -$2.89M | -$1.24M | |
| — | — | $2.21M | $45K | $1.19M | $1000 | $5000 | |
| -$40K | -$308K | $1.94M | $62K | -$235K | — | — | |
| -$11.13M | -$10.21M | -$10.11M | -$10.49M | -$4.04M | -$2.83M | -$1.22M | |
| USD/shares | -$0.44 | -$0.54 | -$0.74 | -$0.91 | -$0.65 | -$0.51 | -$0.26 |
| USD/shares | -$0.44 | -$0.54 | -$0.74 | -$0.91 | -$0.65 | -$0.51 | — |
| shares | 25.48M | 18.6M | 13.64M | 11.5M | 6.24M | — | — |
| shares | 25.48M | 18.6M | 13.64M | 11.5M | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2023: $704K in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.